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Purpose: To report the development and therapeutic evaluation of a liposomal nanocarrier for 
sustained release of latanoprost, in the rabbit eye.
Methods: We fabricated latanoprost-loaded egg-phosphatidylcholine (EggPC) liposomes 
using the film hydration technique. The delivery vehicles were nano-sized (Z avg = 109 ± 18 nm), 
had a narrow poly dispersity index (PDI = 0.19 ± 0.04), and a very high   loading   efficiency 
(94% ± 5%). Based on in vitro data, we evaluated this formulation for lowering   intraocular 
pressure (IOP) in rabbit eyes. Following a single subconjunctival injection of the latanoprost 
loaded formulation, the eyes were clinically monitored and the IOP recorded.
Results: Latanoprost-loaded EggPC liposomes demonstrated a high drug/lipid mole ratio of 
0.181, remained stable for at least 6 months on storage (4°C), and at least 1 month at 25°C. A slow 
and sustained release of 60% of latanoprost was achieved by 14 days in the in vitro release study. 
The same formulation demonstrated a greater sustained IOP lowering effect compared with daily 
administration of topical latanoprost beyond 90 days (4.8 ± 1.5 vs 2.5 ± 0.9 mmHg; P , 0.001). 
No signs of inflammation were evident in the eyes from slit-lamp examination analysis.
Conclusion: The loading required for a long-term sustained delivery of latanoprost for up to 
90 days in the rabbit eyes was achieved with EggPC liposomes. A single injection of latanoprost-
loaded EggPC liposomes can lower the IOP for up to 90 days, with a greater IOP lowering effect 
than daily topical administration of latanoprost.
Keywords: nanomedicine, nanoliposomes, EggPC, latanoprost, sustained ocular delivery, 
glaucoma
Introduction
Intraocular pressure (IOP) remains the key modifiable risk factor in glaucoma – 
a progressive optic neuropathy resulting in irreversible visual field loss that affects more 
than 60 million worldwide and is the second leading cause of blindness after cataract.1 
The first line treatment of glaucoma is topical medications to lower the IOP, thereby 
delaying damage to the optic nerve from elevated IOP. However, daily application, 
due to poor ocular bioavailability and other long-term side effects such as allergy and 
intolerance to medications, have negative effects on patient compliance, which leads to 
disease progression from suboptimal medical management of the disease resulting in 
poor IOP control.2–4 Latanoprost, a lipophilic drug usually delivered in the form of an 
oil/water emulsion (Xalatan®, Pfizer, Catalent Pharma Solutions, Woodstock, IL), is very 
effective in reducing IOP in glaucoma.5 However, latanoprost acid, the hydrolyzed active 
product, is more hydrophilic and experiences a higher penetration resistance through 
the epithelium and endothelium of the cornea and hence lower bioavailability.6International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Liposomes, which have been shown to be   biocompatible 
nanocarriers for ocular use, allows for delivery of both 
the lipophilic drug molecule as well as its hydrophilic 
active products, due to its physical structure of a polar 
core and lipophilic bilayer.7 Liposomal encapsulation 
protects drug molecules from enzymatic hydrolysis in the 
physiological environment while in circulation, and thus 
increases stability. Previous studies on topical application 
of liposomes   demonstrated poor penetration into the eye,8–11 
however, while studies on subconjunctival injections on 
other IOP-lowering drugs showed limited sustainability.9,11,12 
  Furthermore, it is not clearly understood whether drug-loaded 
liposomes in the subconjunctiva behave like a depot system 
or   actually undergo circulation and endocytosis.12 The design 
of carriers for sustained delivery in the eye necessitates the 
use of a formulation that has the required optical clarity with 
sufficient drug loading efficiency for administration. Also, 
drug-loaded carriers should be stable under testing   conditions 
in vitro and in vivo. The size of the nanocarriers might 
also facilitate the delivery of the drug through the various 
anatomical structures of the eye (conjunctiva and sclera) to 
reach the targeted site (ciliary body) more efficiently, with 
increased bioavailability.
Thus the challenge is to formulate latanoprost into a 
  liposomal vehicle such that its delivery is sustained over 
  several weeks to months, after a single subconjunctival 
  injection. In this study, we developed and optimized a 
  liposomal formulation that provides prolonged delivery, and 
confirmed its safety and efficacy in the rabbit eye.
Materials and methods
Materials
Egg-phosphatidylcholine (EggPC . 95 wt%) was purchased 
from NOF Corporation (Tokyo, Japan). Polycarbonate filter 
membranes of sizes (0.2, 0.1, and 0.08 µm) and drain discs 
were purchased from Northern Lipids Inc (Burnaby, Canada). 
Cellulose ester dialysis bags (16 mm dia × 10 m flat width) were 
obtained from Spectrum Laboratories (Rancho Dominguez, 
CA). Chemicals for phospholipid analysis such as ammonium 
thiocyanate and ferric chloride hexahydrate were purchased 
from Sigma (Ronkonkoma, NY). Sodium phosphate dibasic 
anhydrous (Na2HPO4), potassium phosphate monobasic 
anhydrous (KH2PO4), potassium chloride (KCl), and sodium 
chloride (NaCl) salts were purchased from Sigma and used 
without further purification. Latanoprost was purchased from 
Sinophram Chemical Reagent Co Ltd, Senyang, China. The 
water used in all the experiments was from MiliQ purifica-
tion system with a resistivity of at least 18.2 ± 0.2 mΩ cm. 
All solvents were purchased from Tedia (Fairfield, OH), and all 
solvent drug estimation was conducted using high performance 
liquid chromatography (HPLC) grade (.99% purity).
Methods
Preparation of large unilamellar vesicles
A thin film hydration technique was used to formulate latano-
prost loaded EggPC liposomes as described   elsewhere.12 
Briefly, known amounts of phospholipid EggPC (lipid 
concentration, 18 mM) were weighed and dissolved in 
chloroform:methanol (2:1, vol/vol) solvent mixture. A known 
volume of the drug solution of latanoprost (2 mg/mL stock 
solution in acetonitrile) was added to the lipid solvent   mixture 
maintained at 40°C. An initial drug:lipid mole ratio of 0.154 
was used. The solvent mixture was removed from the round 
bottom flask using a rotary evaporator (IKA® RV 10, IKA® 
Werke GmbH & Co. KG, Staufen, Germany) connected to a 
water bath (IKA® MB 10 basic, IKA® Werke GmbH & Co. 
KG, Germany) maintained at 40°C. To completely eliminate 
any trace of residual solvent, the flask was rotated at 100 rpm, 
under low pressure for an hour. A thin, drug-loaded, lipid film 
was obtained and to this film, isotonic phosphate-buffered 
saline (PBS) (150 mM, pH 5.5) buffer was added to form 
multilamellar vesicles (MLVs). Subsequent size reductions 
were carried out by sequential extrusion of MLVs (10 times) 
through polycarbonate filters of size (0.2 µm/0.08 µm), fitted 
in a bench top extruder, purchased from Northern Lipids Inc, 
Canada. At the end of this step, large unilamellar vesicles 
(LUVs) with a size distribution of 0.09–0.12 µm were 
obtained. All of the above-mentioned steps were performed 
under aseptic conditions. All glassware and the PBS solution 
(filtered through 0.2 µm filter), was sterilized by autoclaving, 
and the entire procedure was performed under a laminar flow 
hood (ESCO, Singapore).
characterization of drug-loaded  
eggPc liposomes
size
The average size of the liposomes as well as the size distribu-
tion (poly dispersity index) was carried out using the Malvern 
Zetasizer Nano ZS (Worcestershire, UK). The vesicle sizes 
were continuously monitored after preparation, on storage 
(4°C and 25°C), and after drug release in vitro.
Lipid analysis
The phospholipid concentration was estimated using 
colorimetric method as described elsewhere.13 A six point 
calibration was prepared for EggPC lipids (peak wavelength International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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absorbance at 470 nm) and was later used for estimation 
of the concentration of lipids in vesicles obtained after 
extrusion. The amount of phospholipids after extrusion was 
estimated to be around 80%–85% (by mass). 
estimation of drug concentration using high 
performance liquid chromatography method
The concentration of the latanoprost was estimated using an 
HPLC system (Agilent series 1200, Santa Clara, CA). The 
chromatographic separation was performed on reverse phase 
Eclipse-XDB C18 column (5 µm, 4.6 mm ID × 250 mm) 
using mobile phase as acetonitrile (ACN):Water at 70:30 
(v/v)   proportions. The flow rate was maintained at 1.0 mL/
min and wavelength was set at 210 nm. The retention time 
was 4.3 min and the temperature of the column was main-
tained at 25°C. The released latanoprost concentration was 
estimated directly from the collected samples in pH 7.4. 
The total drug concentration was estimated by breaking the 
liposomes in a solvent system, such as isopropyl alcohol 
in a volume ratio of 1:4. The broken lipid mass was then 
centrifuged and isolated from the rest of solution by ultra-
centrifugation at 13,000 rpm for 30 minutes. The supernatant 
was diluted 50 times with PBS pH 7.4 and analyzed for total 
drug concentration. The total and released drug values were 
estimated in comparison with a standard calibration curve 
of latanoprost in PBS pH 7.4. The drug loading efficiency 
was calculated as follows:
Drug loading efficiency (%) = 100 × (Amount of drug retained
  /Amount of drug taken initially)
Drug partition coefficient estimation
A lipophilic drug such as latanoprost distributes between 
a lipid bilayer and the aqueous continuous phase, and the 
concentration ratio between these two phases   determines 
the partition coefficient. The values for   partition   coefficient 
were estimated from the MLVs before the extrusion step. 
Briefly, known sample volumes were   collected in microfuge 
tubes and centrifuged at 10000 rpm for 30 minutes. Due to 
the large size of MLVs, in the micron size ranges, we were 
able to separate out the fractions of the lipid pellet from the 
clear supernatant. The drug estimated from the supernatant is 
a measure of   continuous (buffer) phase drug   concentration, 
while this amount when subtracted from the total drug 
concentration yields drug partitioned into the bilayer. Thus, 
the drug   partition coefficient (P.C.) in MLVs was estimated 
using the   following expression (each concentration in mass 
per unit volume):
P.C. = (Total amount of drug-amount of drug in buffer)
  /(amount of drug in buffer)
The final drug:lipid ratios in the liposomal   formulation 
obtained after extrusion in LUVs were estimated as follows:
Final drug to lipid (D/L) mole ratio in LUVs after extrusion 
  = moles of drug left/moles of the lipid
Drug release studies
A dialysis method was followed to evaluate the release of 
latanoprost from EggPC liposomes. Briefly, 1 mL of drug-
loaded liposomal suspension was taken in a cellulose ester 
dialysis bag (100 kD MWCO, 1.6 cm dia × 6 cm length) and 
dialyzed against 40 mL of PBS pH 7.4. The dialysis bag was 
continuously agitated in an orbital shaker   (Sartorius Cer-
tomat®, Sartorius Stedim North America Inc, Bohemia NY) 
maintained at 37°C at 50 rpm. To maintain dynamic sink 
conditions, similar to in vivo, the dialysate was completely 
exchanged with fresh PBS pH 7.4 buffer every 24 hours. 
Aliquots were withdrawn from the release medium and were 
filtered through a 0.2 µm syringe filter and assayed for the 
released drug. The volume of liposomes and sizes of vesicle in 
the dialysis tube were recorded at the end of release study to 
check for any dilution effect and/or size change of vesicles.
Estimation of latanoprost in ocular fluids  
(aqueous and vitreous humor)
The aspirated aqueous and vitreous humors were   collected 
in sterile 1 mL syringes. The humors were directly   filtered 
through 0.2 µm sterile syringe filters (  regenerated c  ellulose) 
into microfuge tubes. The samples in the microfuge tubes 
were then vortexed and ultra-centrifuged at 13,000 rpm for 
15 minutes to remove any particulates/debris. The supernatant 
was then aspirated into a syringe and transferred into amber 
colored HPLC vials with insets. The latanoprost amount in 
these fluids was estimated by the HPLC method as earlier 
described, using the volume of aqueous humor as 0.15 mL 
and vitreous humor as 0.3 mL from a rabbit eye.
In vivo evaluation in the rabbit eye
surgical technique
Sixteen female New Zealand White rabbits were used in this 
study. The baseline IOP was measured twice daily using a 
calibrated Tono-pen® XL (Reichert Ophthalmic Instruments, 
Depew, NY) for 7 days in all rabbits. The   rabbits were divided 
into two treatment groups: (i) Group A (8 rabbits, 16 eyes) 
received one subconjunctival injection of latanoprost-loaded 
liposomes using a 27-gauge needle; (ii) Group B (8 rabbits, International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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16 eyes) received one eye drop of topical latanoprost daily. 
All procedures were performed under topical anesthesia 
(amethocaine 2.5%) by a single surgeon (MA). Essentially, 
the eye was cleaned with 50% povidone iodine and 0.1 mL 
of liposome was injected in the subconjunctival space in the 
superior temporal region of each eye. Topical   chloramphenicol 
2.5% was administered to the operated eye daily for 5 days. 
We obtained approval from the SingHealth Institute Animal 
Care and Use Committee and all procedures were performed 
in accordance with the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of Animals 
in Ophthalmic and Vision Research.
clinical evaluation, slit-lamp microscopy,  
anterior segment imaging
Twice-daily IOP measurements were conducted at the same 
time everyday using a calibrated Tono-pen, and visual inspec-
tion of all eyes after injections, or topical latanoprost for 
signs of conjunctival irritation, inflammation or infection at 
the injection site. Slit-lamp microscopic examination of the 
exterior and anterior chamber of the eyes was performed 
before the injections and weekly thereafter. Anterior seg-
ment photographs and anterior segment optical coherence 
tomography (AS-OCT) of the eyes that received the liposome 
formulation were performed at weekly intervals. The rab-
bits were also monitored for any gross changes such as eye 
discharge, squinting, or abnormal behavior suggesting pain 
or severe discomfort. A modified Hackett McDonald ocular 
score was used to grade conjunctival injection, conjunctival 
swelling, discharge, corneal clarity, and aqueous flare.14
statistical analysis
Statistical analysis included descriptive statistics, where 
the mean and standard deviation (SD) was calculated for 
the continuous variables; while frequency distribution and 
percentages were used for categorical variables. Comparisons 
between categorical variables were conducted by Fisher exact 
test, whereas the one-way analysis of variance (ANOVA) 
test was used for means. A P value ,0.05 was considered 
statistically significant.
Results
Drug-loading efficiency
The particle sizes of latanoprost loaded EggPC liposomes 
were in the nanometer range (Z avg = 109 ± 18 nm), with a 
narrow poly dispersity index (0.19 ± 0.04). A high loading 
efficiency of latanoprost in EggPC liposomes was achieved 
(94% ± 5%) for an initial D/L mole ratio of 0.154. The final 
latanoprost concentration in EggPC liposomes after extrusion 
was estimated to be greater than 1 mg/mL, which is 20-fold 
higher than commercially available topical latanoprost 
(50 µg/mL) that is administered daily.15 The final drug/lipid 
mole ratio value was estimated to be 0.181. The   concentration 
of the drug used for in vivo studies was 1.18 mg/mL. The 
reason for the higher final value of drug/lipid mole ratio was 
the partial loss of lipids during extrusion.
In vitro size stability
The changes in the size of the liposomes upon storage as 
well as during drug release were continuously monitored in 
a Zetasizer (Malvern Instruments, Malvern, UK) at various 
  temperatures. As shown in Table 1, the unloaded EggPC 
vesicles showed a significant change in the vesicle size and 
poly dispersity, compared with latanoprost-loaded EggPC 
liposomes. The unloaded vesicles aggregated on storage, 
and micron sized particles were observed within 6 months 
upon storage at 4°C. However, the latanoprost-loaded EggPC 
liposomes were stable with respect to aggregation for at least 
6 months on storage at 4°C and at least for a month at 25°C.
In vitro drug release from eggPc vesicles
The release of latanoprost from the liposomes was evaluated 
by a dialysis technique and expressed in terms of cumulative 
drug release (%) over time as shown in Figure 1. A slow and 
Table 1 size measurement of liposomes during storage at 4°c, 25°c and after drug release in PBs buffer (ph 7.4) at 37°c
Type of  
liposome
Size measurement, nm (PDI)
Temperature (°C)
4°C 25°C 37°C
Duration (months)
0 1 2 6 1
After in vitro 
drug release
eggPc liposome 79.8 (.09) 114.4 (0.19) 180.3 (0.34) 1200 (0.46) NA NA
Latanoprost loaded  
eggPc liposomes
86.6 (0.17) 83.91 (0.14) 89.98 (0.14) 86.38 (0.11) 82.88 (0.18) 82.02 (0.08)
Abbreviations: eggPc, egg-phosphatidylcholine; PBs, phosphate-buffered saline; PDI, poly dispersity index.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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sustained release of the drug was achieved with 60% of the 
drug being released at the end of 2 weeks. In addition, the 
size changes were minimal at the end of the in vitro drug 
release period (Table 1).
Based on the data derived from loading, release, and 
stability studies, we then investigated the efficacy of IOP 
lowering from latanoprost loaded-EggPC liposomes (D/L 
mole ratio of 0.181) in rabbit eyes. The dose/day was targeted 
for at least 2 weeks, similar to that of topical latanoprost 
(1.5 µg/drop/day); to sustain delivery at a level comparable 
to or higher than the eye drop, about 1 mg/mL in 100 µL of 
liposomal injection is necessary.16 The actual amount of drug 
released per day from EggPC liposomes was compared to 
topical latanoprost formulation as shown in Figure 2. The 
consequences of the higher initial burst seen with liposomes, 
which would probably be indicated by the presence of a very 
sudden lowering of the IOP, were carefully monitored in the 
animals.
Drug partition coefficient value
The ratio of the drug concentration in the lipid phase to that 
in the continuous phase determines the partition coefficient 
(P.C.). A partition coefficient value of 28 ± 5 was estimated 
for EggPC multilamellar liposomes. This value translates to 
a greater than 95% of the drug associated/entrapped within 
the bilayer. The partition coefficient value obtained for 
EggPC liposomes was significantly higher than observed 
with dipalmitoylphosphatidylcholine (DPPC) liposomes 
(11 ± 1).16 This indicates that a more preferential association 
of latanoprost was observed with the less ordered liposomal 
structures derived from EggPC than in a more ordered lipo-
somal structures derived from DPPC.
In vivo study
Intraocular pressure
The baseline IOP was 13.6 ± 0.3 mmHg for all 16 rabbits and 
there was no difference between the two treatment groups 
(P = 0.80). We found a significantly higher mean reduction 
of IOP in the eyes that received a subconjunctival injec-
tion of latanoprost-loaded liposomes compared with eyes 
administered daily topical latanoprost eye drops. This effect 
was maintained for 90 days (4.8 ± 1.5 vs 2.5 ± 0.9 mmHg; 
P , 0.001) (Figure 3). Furthermore, the initial burst release 
seen in vitro did not appear to result in an excessive IOP 
reduction (,2 mmHg).
Modified Hackett–Macdonald Scores
We compared the Modified Hackett–Macdonald Scores of 
the injection site, by calculating the percent increase in score 
from pre-injection to the end of the study (90 days) in each 
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treatment group. There was no significant difference in the 
scores between the two treatment groups (10% ± 0.5% vs 
12% ± 0.6%; P = 0.32). Neither did we observe any clinical 
complications such as conjunctival infections or anterior 
chamber inflammation on slit-lamp examination.
Anterior segment optical coherence tomography 
(As-OcT)
AS-OCT scans confirmed subconjunctival location of 
  liposomes in the superior temporal aspect of each rabbit 
eye immediately after injections as shown in Figure 4. 
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Subsequent AS-OCT scans performed reveal no abnormal 
local tissue scarring or scleral thinning at the injection sites 
as shown in Figure 5. At the end of the experimental period 
the eyes were enucleated and the ocular fluids examined. 
There were unrecordable amounts of latanoprost detected 
in both aqueous and vitreous samples by HPLC analysis 
from both groups.
Discussion
Our study revealed that a single subconjunctival injection of 
latanoprost-loaded EggPC liposomes can effectively lower 
the IOP in rabbit eyes for at least 90 days. This IOP-lowering 
effect was significantly greater than once-daily topical 
  latanoprost, the current standard treatment in glaucoma 
patients. These observed results are also consistent with 
our in vitro results, which demonstrate a slow and sustained 
release of latanoprost, with stability in liposome size and 
structural integrity. The sustained reduction of IOP in rab-
bit eyes is encouraging. To our knowledge, no other reports 
show such a significant effect of latanoprost sustained-release 
using liposomes (or any other carriers) in the animal eye. 
We also demonstrated that the liposome formulation was 
well tolerated as evidenced from the lack of recorded ocular 
irritation or inflammation.
We have developed a nano-sized liposomal formulation 
with a narrow polydispersity, and achieved a high D/L mole 
ratio of 0.181 using EggPC liposomes. While a similar, high 
D/L, mole ratio for other lipophilic drugs such as paclitaxel 
(0.15),17 aryl-imidazole compound (ML220) (0.29),18 and 
curcumin (0.07)19 have been reported, the D/L mole ratio 
for other hydrophobic drugs such as ibuprofen (0.02)20 
and cisplatin (0.05) were low.21 We previously achieved a 
maximum D/L mole ratio of 0.104 using DPPC liposomes, 
synthesized from a saturated lipid that maintained an IOP 
lowering effect for 50 days in the rabbit eyes.16 Therefore 
this is a significantly improved formulation in terms of the 
D/L mole ratio using EggPC, with a longer IOP lowering 
effect in the same species.
Our storage stability analysis showed that liposomes 
(without latanoprost) aggregated to micron size par-
ticles within 6 months of storage at 4°C. This finding is 
consistent with previously reported studies with EggPC 
liposomes.22–24 In contrast, notable disintegration of the 
carrier is usually observed for hydrophobic drug-loaded 
liposomes, hence limiting its potential for a sustained drug 
delivery.18,25,26 Such instability in size greatly limits the use 
of liposomal carriers for ocular drug delivery. In our study, 
the latanoprost-loaded liposome formulation had minimal 
size changes detected at both 4°C (.6 months) and 25°C 
(.1 month), suggesting that latanoprost does not destabi-
lize the bilayer of EggPC liposomes, and may even help to 
improve the stability under storage conditions, similar to 
the effects of cholesterol.22,27 This is further supported by 
similar stability of high-loading curcumin into EggPC and 
paclitaxel into mixed liposomes composed of saturated and 
unsaturated lipids.19,25
As mentioned above, using the partition coefficient 
  values, we find that approximately 95% of latanoprost is 
  associated in the bilayer of EggPC liposomes, while the 
remaining 5% of the drug exists as free drug in the   continuous 
phase, for a D/L mole ratio of 0.181. Because very low 
Figure 4 (A) Injection of subconjunctival liposome formulation. (B) Immediate 
post-injection of liposome formulation. A subconjunctival bleb is clearly seen where 
the liposomal formulation has been administered. (C) slit-lamp photograph of eye 
post-injection at Day 90. The conjunctiva is white and the eye is quiet. There is no 
evidence of conjunctival hyperaemia, inflammation, or infection at the site of or 
surrounding the injection area. (D) slit-lamp photographs of eye receiving one drop 
of topical latanoprost daily at Day 90.
Figure  5  Anterior  segment  optical  coherence  tomography  confirming  the 
subconjunctival  location  of  the  liposome  formulation  immediate  post-injection 
(A) and no evidence of scleral thinning or conjunctival scarring at Day 90 (B).International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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amounts of free drug was present, no additional step for 
removal was necessary.
A sustained release of drugs to improve therapeutic 
efficacy in the management of glaucoma, has now been 
considered as a major focus in pharmaceutical development 
for glaucoma medications. Various delivery systems are now 
being explored. The ideal system should have minimal risks 
to the patient and be as comfortable as possible to deliver. 
Liposomes are a potential candidate for providing sustained 
release of ocular drugs. However, the major limitation with 
topical liposomes is the lack of sustained efficacy, due to bio-
logical barriers in the eye and clearance from tear dilution.7 
Different routes of injectable liposome systems tested include 
periocular, intravitreal, and subconjunctival.28,29 Moreover, 
recent reports have shown the benefits of subconjunctival 
injections with improved absorption rates and sustained 
efficacy, using low molecular weight heparin,30 streptokinase, 
and clodronate.31,32 Here, we show for the first time that the 
subconjunctival delivery of liposomes can clearly bypass 
these barriers thereby allowing these nanocarriers to be poten-
tially used as a platform for sustained release of drugs.
Moon et al suggested that the liposomes behaved like a 
depot system in the subconjunctival space.30 They suggested 
a lack in systemic clearance of liposomes in the subconjunc-
tival space, which remained at the site of injection, probably 
due to the larger particle size (∼550 nm) of the liposomes. 
There are several limitations in our pilot study, such as the 
small numbers and study duration. However in our study, we 
successfully achieved a sustained reduction in IOP over an 
extended timeframe of 90 days from a single subconjuncti-
val injection in the rabbit eye. We also demonstrated safety 
and tolerance of this particular liposomal injection. The 
initial high burst of the drug observed in the first few days 
of the in vitro release studies requires further understanding 
and refinement of the formulation, which we are currently 
  performing. In addition, future studies are planned to track 
the movement of liposomes in the ocular structures after they 
have been injected as well as the stability of the latanoprost 
within the liposomes during this process. Nonetheless, the 
initial outcomes from our study report are promising and 
point to significant benefits over the current eyedrop regime 
for glaucoma.
Conclusion
In conclusion, we report a liposomal formulation with EggPC 
to provide sustained release of latanoprost in the rabbit eye 
for up to 90 days after a single subconjunctival injection. 
Further detailed studies on the pharmacodynamics of these 
liposomes within the ocular tissues will determine its future 
potential clinical application.
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